Free Trial
NYSEAMERICAN:ARMP

Armata Pharmaceuticals (ARMP) Stock Price, News & Analysis

Armata Pharmaceuticals logo
$2.40 +0.05 (+2.13%)
As of 07/23/2025 04:10 PM Eastern

About Armata Pharmaceuticals Stock (NYSEAMERICAN:ARMP)

Key Stats

Today's Range
$2.32
$2.44
50-Day Range
$1.35
$2.46
52-Week Range
$0.90
$3.01
Volume
4,468 shs
Average Volume
70,455 shs
Market Capitalization
$86.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
Consensus Rating
Buy

Company Overview

Armata Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

ARMP MarketRank™: 

Armata Pharmaceuticals scored higher than 46% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Armata Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Armata Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Armata Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Armata Pharmaceuticals are expected to decrease in the coming year, from ($0.95) to ($1.70) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Armata Pharmaceuticals is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Armata Pharmaceuticals is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Armata Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    0.96% of the float of Armata Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Armata Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Armata Pharmaceuticals has recently decreased by 22.74%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Armata Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Armata Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.96% of the float of Armata Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Armata Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Armata Pharmaceuticals has recently decreased by 22.74%, indicating that investor sentiment is improving significantly.
  • Search Interest

    Only 1 people have searched for ARMP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Armata Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    84.50% of the stock of Armata Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 3.57% of the stock of Armata Pharmaceuticals is held by institutions.

  • Read more about Armata Pharmaceuticals' insider trading history.
Receive ARMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Armata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARMP Stock News Headlines

Armata Pharmaceuticals Inc.
Buffett to put 90% of his money in this one stock?
CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accounting firms like Deloitte and KPMG, Joel Litman (who’s also a member of the Global CFA Institute) figured out a unique, less-risky way to grow rich in the stock market. Litman says you don’t need dozens of investments, overpriced advisers, or hedge funds. You just need these 3 stocks, which have helped Litman’s own mom earn 3,400%.
See More Headlines

ARMP Stock Analysis - Frequently Asked Questions

Armata Pharmaceuticals' stock was trading at $2.00 at the beginning of 2025. Since then, ARMP stock has increased by 20.0% and is now trading at $2.40.

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) posted its earnings results on Tuesday, November, 14th. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.02. The firm had revenue of $1.23 million for the quarter, compared to analysts' expectations of $0.90 million.

Armata Pharmaceuticals' top institutional investors include GSB Wealth Management LLC (0.08%).
View institutional ownership trends
.

Shares of ARMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Armata Pharmaceuticals investors own include VBI Vaccines (VBIV), Altimmune (ALT), Vaxart (VXRT), Pfizer (PFE), Advanced Micro Devices (AMD), Co-Diagnostics (CODX) and Amarin (AMRN).

Company Calendar

Last Earnings
11/14/2023
Today
7/24/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSEAMERICAN:ARMP
CIK
921114
Employees
70
Year Founded
N/A

Price Target and Rating

High Price Target
$9.00
Low Price Target
$9.00
Potential Upside/Downside
+275.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.64)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$18.92 million
Net Margins
N/A
Pretax Margin
-9.07%
Return on Equity
N/A
Return on Assets
-25.06%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.12
Quick Ratio
0.12

Sales & Book Value

Annual Sales
$5.17 million
Price / Sales
16.80
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.33) per share
Price / Book
-1.80

Miscellaneous

Outstanding Shares
36,190,000
Free Float
5,610,000
Market Cap
$86.86 million
Optionable
Not Optionable
Beta
0.94
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NYSEAMERICAN:ARMP) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners